Genotyping of Cytomegalovirus From Patients in Israel
Recruitment status was: Recruiting
|Study Design:||Observational Model: Natural History
Time Perspective: Cross-Sectional
Time Perspective: Retrospective
|Official Title:||Cytomegalovirus Glycoprotein B Genotypes in Israeli Patients: Relationship Between CMV Genotype, Clinical and Demographic Factors|
|Study Start Date:||September 2005|
The study aims at finding association between CMV viral load and viral glycoprotein B genotype and the clinical status of patients suffering from CMV infection. Bone marrow transplant patients are at increased risk of developing severe CMV disease and are routinely followed for viral load. Fetuses are also at high risk for developing severe malformations and neurological defects following maternal primary infection during pregnancy. Therefore amniotic fluid from women diagnosed with CMV infection is examined for CMV presence. Newborns having congenital defects are tested for CMV excretion.
There is not yet any confirmed marker for assessment of the potential severity of the viral infection and for prognosis. Therefore we shall attempt to find association between the viral load and genotype and the clinical status.
CMV DNA samples prepared at the Central Virology Laboratory from clinical specimens obtained from patients for diagnostic purposes will be coded and then subjected to viral load analysis using real-time PCR. The gB genotype will be determined by either of two methods described in the literature: (a) PCR and RFLP (b) PCR and sequencing.
Relevant clinical data will be retrieved from the patients clinical records and saved as coded information to match the samples. Bone marrow transplant patients will be followed for prolonged periods covering repeated viral reactivation events. Clinical records from mothers and newborns will be matched when present. Otherwise maternal and newborn samples will be kept as is.
Statistical analysis will be performed to try and find association between the clinical status of patients, the viral load and the viral genotype.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00228202
|Contact: Ella Mendelson, PhDfirstname.lastname@example.org|
|Contact: Naty Keller, MD/PhDemail@example.com|
|Central Virology Laboratory, Chaim Sheba Medical Center Tel-Hashomer||Recruiting|
|Ramat Gan, Israel, 52621|
|Contact: Ella Mendelson, PhD 972-3-530-2421 firstname.lastname@example.org|
|Contact: Zehava Grossman, PhD 972-3-530-2458 email@example.com|
|Principal Investigator: Ella Mendelson, PhD|
|Sub-Investigator: Musa Hindiyeh, PhD|
|Study Director:||Naty Keller, MD/PhD||Sheba Medical Center|